Øget aliskiren- eksponering ved samtidig administration af CYP3A4- hæmmere, som også hæmmer P- gp, kan derfor forventes (se også P- glycoprotein interaktioner herunder).
Increased aliskiren exposure during co-administration of CYP3A4 inhibitors that also inhibit P-gp can therefore be expected (see P-glycoprotein interactions below).